A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older

Sanofi Pasteur, a Sanofi Company24 sites in 2 countries1,162 target enrollmentJanuary 6, 2025

InterventionsTrivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 TIV mRNA-neuraminidase (NA)TIV mRNA-HA Vaccine 2 Quadrivalent Influenza Standard Dose Vaccine Quadrivalent Influenza Vaccine High Dose

DrugsTrivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 TIV mRNA-neuraminidase (NA)TIV mRNA-HA Vaccine 2 Quadrivalent Influenza Standard Dose Vaccine Quadrivalent Influenza Vaccine High Dose

Overview

Phase: Phase 1
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Conditions: Influenza
Sponsor: Sanofi Pasteur, a Sanofi Company
Enrollment: 1162
Locations: 24
Primary Endpoint: Number of participants with immediate unsolicited systemic adverse events (AEs)
Status: Active, not recruiting
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.

Detailed Description

Study details include the following: * Study Duration: approximately 12 months for each participant * Treatment: 1 injection of hexavalent vaccine, trivalent vaccine, or active control * Visit frequency: Day (D) 01, D03, D09, D29, and D181; D366 (telephone call) * Dose escalation with sequential enrollment of sentinel cohorts followed by parallel enrollment of the main cohort

Registry

clinicaltrials.gov

Start Date

January 6, 2025

End Date

April 16, 2026

Last Updated

11 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Sanofi Pasteur, a Sanofi Company

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participant aged 50 years on the day of inclusion
•A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
•Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.
•Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.
•A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours prior to administration of study intervention.

Exclusion Criteria

•Participants are not eligible for the study if any of the following criteria are met:
•Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
•Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA vaccine
•Previous history of myocarditis, pericarditis, and/or myopericarditis
•Known history of previous episodes of Guillain-Barré syndrome, neuritis (including Bell's palsy), convulsions, encephalitis, transverse myelitis, and vasculitis
•Participants with an electrocardiogram that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
•Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment
•Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination based on Investigator's judgment
•Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
•Moderate or severe acute illness / infection (according to investigator's judgement) or febrile illness (temperature ≥ 38.0°C \[≥ 100.4°F\]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.

Arms & Interventions

Group 1 - Hexavalent (Combination 1)

Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)

Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1

Group 1 - Hexavalent (Combination 1)

Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)